Imagen de Portada

Beyond the Fragility Index

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Piero Quatto, Enrico Ripamonti, Donata Marasini
Formato:	Artículo Open Access
Publicado:	Wiley 2024
Materias:	Pharmaceutical Statistics
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Methodological Approaches for the Estimation of Confidence Intervals on Partial Youden Index Under Verification Bias
por: Sihan Jia, et al.
Publicado: (2026)

Frailty model with change points for survival analysis
por: Masahiro Kojima, et al.
Publicado: (2024)

Dynamic borrowing of historical controls adjusting for covariates in vaccine efficacy clinical trials
por: Andrea Callegaro, et al.
Publicado: (2024)

Time‐to‐event estimands and loss to follow‐up in oncology in light of the estimands guidance
por: Jonathan M. Siegel, et al.
Publicado: (2024)

Simulation‐based sample size calculations of marginal proportional means models for recurrent events with competing risks
por: Julie Funch Furberg, et al.
Publicado: (2024)

Comparing various Bayesian random‐effects models for pooling randomized controlled trials with rare events
por: Minghong Yao, et al.
Publicado: (2024)

Predictive Ppk calculations for biologics and vaccines using a Bayesian approach – a tutorial
por: Jos Weusten, et al.
Publicado: (2024)

Principles for Defining Estimands in Clinical Trials—A Proposal
por: Tobias Mütze, et al.
Publicado: (2024)

Quality by Design for Preclinical In Vitro Assay Development
por: Jonathan Jones, et al.
Publicado: (2024)

Applying the Estimand Framework to Non‐Inferiority Trials
por: Helle Lynggaard, et al.
Publicado: (2024)

Current developments of the estimand concept
por: Alexander Fierenz, et al.
Publicado: (2024)

Comparative Analyses of Bioequivalence Assessment Methods for In Vitro Permeation Test Data
por: Sami Leon, et al.
Publicado: (2024)

Futility Interim Analysis Based on Probability of Success Using a Surrogate Endpoint
por: Ronan Fougeray, et al.
Publicado: (2024)

Pre‐Posterior Distributions in Drug Development and Their Properties
por: Andrew P. Grieve
Publicado: (2024)

A Model‐Based Trial Design With a Randomization Scheme Considering Pharmacokinetics Exposure for Dose Optimization in Oncology
por: Jun Zhang, et al.
Publicado: (2024)

Confidence Intervals for the Risk Difference Between Secondary and Primary Infection Based on the Method of Variance Estimates Recovery
por: Chao Chen, et al.
Publicado: (2024)

Mixture Experimentation in Pharmaceutical Formulations: A Tutorial
por: Lynne B. Hare, et al.
Publicado: (2024)

To Dilute or Not to Dilute: Nominal Titer Dosing for Genetic Medicines
por: Paul Faya, et al.
Publicado: (2024)

Information‐based group sequential design for post‐market safety monitoring of medical products using real world data
por: Zhiwei Zhang, et al.
Publicado: (2024)

Issue Information
Publicado: (2024)

Simultaneous Inference Using Multiple Marginal Models
por: Ludwig A. Hothorn, et al.
Publicado: (2024)

Bayesian Response Adaptive Randomization for Randomized Clinical Trials With Continuous Outcomes: The Role of Covariate Adjustment
por: Vahan Aslanyan, et al.
Publicado: (2024)

Using an early outcome as the sole source of information of interim decisions regarding treatment effect on a long‐term endpoint: The non‐Gaussian case
por: Leandro Garcia Barrado, et al.
Publicado: (2024)

Generalizing Treatment Effect to a Target Population Without Individual Patient Data in a Real‐World Setting
por: Hui Quan, et al.
Publicado: (2024)

A Likelihood Perspective on Dose‐Finding Study Designs in Oncology
por: Zhiwei Zhang
Publicado: (2024)

Tutorial on Firth's Logistic Regression Models for Biomarkers in Preclinical Space
por: Gina D'Angelo, et al.
Publicado: (2024)

Estimation of Treatment Policy Estimands for Continuous Outcomes Using Off‐Treatment Sequential Multiple Imputation
por: Thomas Drury, et al.
Publicado: (2024)

A Personalized Dose‐Finding Algorithm Based on Adaptive Gaussian Process Regression
por: Yeonhee Park, et al.
Publicado: (2024)

What they forgot to tell you about machine learning with an application to pharmaceutical manufacturing
por: Kjell Johnson, et al.
Publicado: (2024)

A Bayesian Hybrid Design With Borrowing From Historical Study
por: Zhaohua Lu, et al.
Publicado: (2024)

Balance diagnostics in propensity score analysis following multiple imputation: A new method
por: Sevinc Puren Yucel Karakaya, et al.
Publicado: (2024)

Real Effect or Bias? Good Practices for Evaluating the Robustness of Evidence From Comparative Observational Studies Through Quantitative Sensitivity Analysis for Unmeasured Confounding
por: Douglas Faries, et al.
Publicado: (2024)

Shrinkage priors for isotonic probability vectors and binary data modeling, with applications to dose–response modeling
por: Philip S. Boonstra, et al.
Publicado: (2024)

Predicting subgroup treatment effects for a new study: Motivations, results and learnings from running a data challenge in a pharmaceutical corporation
por: Björn Bornkamp, et al.
Publicado: (2024)

Rejoinder to the letter: “Standard and reference‐based conditional mean imputation: Regulators and trial statisticians be aware!”
por: Marcel Wolbers, et al.
Publicado: (2024)

Investigating Stability in Subgroup Identification for Stratified Medicine
por: G. M. Hair, et al.
Publicado: (2024)

WATCH: A Workflow to Assess Treatment Effect Heterogeneity in Drug Development for Clinical Trial Sponsors
por: Konstantinos Sechidis, et al.
Publicado: (2024)

Transporting randomized trial results to estimate counterfactual survival functions in target populations
por: Zhiqiang Cao, et al.
Publicado: (2024)

Potential Bias Models With Bayesian Shrinkage Priors for Dynamic Borrowing of Multiple Historical Control Data
por: Tomohiro Ohigashi, et al.
Publicado: (2024)

Do You Want to Stay Single? Considerations on Single‐Arm Trials in Drug Development and the Postregulatory Space
por: Yulia Dyachkova, et al.
Publicado: (2024)